Search filters

Authors whose works are in public domain in at least one jurisdiction

List of works by Brian Claggett

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

scientific article published on 01 September 2019

Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction

scientific article published on 30 June 2014

C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

scientific article published on 16 September 2016

Cardiac Structure and Function Across the Spectrum of Aldosteronism: the Atherosclerosis Risk in Communities Study

scientific article published in 2022

Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

scientific article

Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial

scientific article

Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure

scientific article published on 30 November 2017

Declining Risk of Sudden Death in Heart Failure

scientific article

ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD.

scientific article published on 7 June 2017

Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF

scientific article published on 17 November 2019

Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.

scientific article published on 02 October 2014

Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan

article

Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial

scientific article published on June 2016

Health-Related Quality of Life Outcomes in PARADIGM-HF.

scientific article

Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial

scientific article published on 10 July 2019

Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum

scientific article published on 12 February 2018

IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure

scientific article published on 01 October 2018

Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia

Impaired left atrial function in heart failure with preserved ejection fraction.

scientific article published on 19 August 2014

Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.

scientific article published on 30 October 2013

Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiot

scientific article

Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus

scientific article published in October 2017

Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial

article

Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Fai

scientific article published on March 2016

Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization

scientific article published in July 2016

Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction

scientific article published on 17 October 2014

Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction

scientific article

Left Atrial Remodeling and Stroke in Patients With Sinus Rhythm and Normal Ejection Fraction: ARIC‐NCS

scientific article published in 2022

Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction.

scientific article

Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease

scientific article published on 04 March 2019

Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure

scientific article published on 4 March 2018

Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study

scientific article

Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality

scientific article

Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program

scientific article published on 2 November 2014

Quantifying the totality of treatment effect with multiple event-time observations in the presence of a terminal event from a comparative clinical study

scientific article published on 25 July 2018

Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus.

scientific article published on 22 May 2015

Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits

article by Li Shen et al published August 2017 in JACC: Heart Failure

Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial

scientific article

Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure

scientific article published on 5 April 2018

Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.

scientific article published on 6 February 2015

Reply: does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF?

scientific article published in October 2014

Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials

scientific article

Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus

scientific article published on 29 May 2017

Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction

scientific article published on 23 February 2014

Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

scientific article published on 19 December 2018

Paulina is supported by:

About Paulina

Help